On October 27, 2025, Alphamab Oncology, a leading biopharmaceutical company specializing in innovative oncology therapeutics, announced the approval by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to launch a Phase III clinical trial for its cutting-edge biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 in patients with HER2-positive advanced colorectal cancer (CRC). This significant regulatory milestone highlights the growing prominence of homegrown Chinese innovation in the global oncology sector, as well as the increasingly pivotal role China's CDE plays in facilitating swift clinical progress for transformational therapies. The new study, designated as JSKN003-005, is a randomized, open-label, multicenter trial designed to rigorously compare the efficacy and safety of JSKN003 versus current standard regimens—including regorafenib, fruquintinib, or trifluridine-tipiracil—in patients who have failed standard lines of therapy containing oxaliplatin, fluorouracil, and irinotecan.

Colorectal cancer remains a critical public health challenge in China, with the International Agency for Research on Cancer (IARC) reporting over 500,000 new CRC cases annually and a high proportion (approximately 83%) diagnosed at an advanced stage. The country has observed persistently poor outcomes for metastatic CRC, with five-year survival for advanced cases remaining below 20 percent. Current treatment regimens provide median progression-free survival of only 2.0 to 3.7 months and overall survival of 7 to 10 months in the post-chemotherapy setting, underlining a profound unmet clinical need. Importantly, no HER2-targeted therapy has been approved in China for colorectal cancer, placing this trial at the forefront of fulfilling a critical market and patient need in the Asian region.

JSKN003 is an innovative biparatopic HER2 ADC developed using site-specific conjugation to the Fc glycans of anbenitamab (KN026) with a Drug-to-Antibody Ratio (DAR) of 4, conferring both molecular stability and a homogeneous drug profile. The ADC binds to two HER2 epitopes on the tumor cell surface, promoting internalization and intracellular release of a topoisomerase I inhibitor payload, resulting in potent anti-tumor activity. Early clinical studies have demonstrated JSKN003’s significant advantages over comparable HER2-targeting ADCs, including improved hematological safety, superior anti-tumor efficacy, and a wider therapeutic window. In recognition of its potential, the NMPA awarded JSKN003 Breakthrough Therapy Designation for HER2-positive advanced CRC in October 2025, as well as for platinum-resistant recurrent ovarian and related cancers, expediting its clinical development timeline.

Alphamab Oncology’s pipeline and strategic partnerships reflect China's broader ambition to ascend the value chain in global pharmaceutical innovation. The company entered a licensing agreement in September 2024 with JMT-Bio Technology, a wholly-owned subsidiary of CSPC Pharmaceutical Group, granting JMT-Bio exclusive mainland China rights to develop and commercialize JSKN003 for tumor indications, while Alphamab retains global manufacturing rights. This partnership highlights the increasing trend of strategic intra-Asia collaborations and the prioritized localization of advanced manufacturing for complex biologic modalities.

Beyond JSKN003, Alphamab Oncology continues to advance an extensive pipeline, leveraging proprietary platforms in single-domain antibodies, bispecific antibodies, glycan-specific conjugation technologies, and dual-payload ADCs. The firm has already achieved commercial success with the world’s first subcutaneous PD-(L)1 inhibitor, Envafolimab, and submitted a new drug application for KN026 for HER2-positive gastric cancer. The company maintains a sharp focus on addressing unmet clinical needs in oncology across Asia and globally by rapidly advancing differentiated, next-generation biologics into late-stage development and market approval.

This latest approval to initiate Phase III studies for JSKN003 underscores the ongoing transformation of China’s biopharmaceutical sector from generic manufacturing to innovation-led drug discovery and development, signaling substantial opportunities for contract development and manufacturing organizations (CDMOs), clinical research providers (CROs), equipment suppliers, and pharma technology partners within the region. The progression of this study is expected to set a benchmark for regulatory collaboration, rapid clinical advancement, and strategic partnerships as advanced biologics enter new therapeutic frontiers across Asia.